·         2009 revenues at or above EUR100 million
·         2009 positive cash-flow of EUR20 million
·         2009 year-end cash balance EUR47.3 million
·         2010 guidance: positive operating income and cash-flow, revenues above
EUR120 million

Mechelen,  Belgium; 29 January 2010 -  Galapagos NV (Euronext:  GLPG) released a
trading  update  based  on  unaudited  preliminary  results for full year 2009.
 Revenues  for  2009 will  be  at  or  above  previously  given guidance of EUR100
million,  more  than  30% growth  over  2008.  Strong  cash flow from Galapagos'
strategic  alliances, combined  with BioFocus'  income and  a successful private
placement  in October 2009, resulted in a year-end cash balance of EUR47.3 million
(compared  to EUR27.3 million at the end  of 2008).  Based on alliance and service
division  revenue  forecasts  for  2010, Galapagos  anticipates  group operating
income and cash flow to be positive in 2010, with revenues above EUR120 million, a
20% increase over 2009.

"Following  our strongest ever financial  and operational performance, Galapagos
now  joins  the  select  group  of  European  biotechnology  firms that are self
sufficient,"  said Onno  van de  Stolpe, CEO  of Galapagos.   "Galapagos' hybrid
business  model has proven a successful blueprint for financial self-reliance in
discovering   and  developing  breakthrough  medicines.   We  believe  that  the
substantial  growth  and  the  profitability  that  we  foresee for 2010 will be
sustainable in future years."

In  its audited financial  reporting scheduled for  5 March 2010, Galapagos will
present 2009 revenues growth fueled by its pharma alliances as well as continued
solid  performance by  BioFocus.  In  its pharma  alliances, Galapagos delivered
strong  results  and  received  milestone  payments  from  all  of  its partners
(GlaxoSmithKline,  Janssen  Pharmaceutica,  Lilly  and  Merck  & Co.).  BioFocus
recorded  strong  margin  improvement  on  top  of  sales  growth,  resulting in
increased profitability for 2009.  The positive cash flow from the alliances and
from  BioFocus  operations,  in  combination  with  the successful EUR18.2 million
private  placement in October 2009, resulted in a year-end 2009 cash position of
EUR47.3  million.  This is EUR9.3 million better  (24%) than the updated guidance of
EUR38 million given in November following the successful private placement.

In  the last quarter of  2009, Galapagos signed an alliance  with Roche in COPD,
expanded  its strategic alliance with Merck  in metabolic diseases and broadened
the  arthritis alliance with  GSK.  Galapagos now  has four programs in clinical
development.   The first  Phase I  study with  metastatic cancer  candidate drug
GLPG0187  was completed, showing  good safety and  promising biomarker results.
Additionally,  two new  clinical trials  were started  in the  fourth quarter of
2009: a Phase  II clinical trial for multiple sclerosis flares with Nanocort and
a  first-in-human study for GLPG0555, part  of the arthritis alliance with GSK.
At  the end of  2009, BioFocus extended its  long-term collaboration with Amgen,
signed  a  compound  management  agreement  with  the  TB  Alliance and received
multiple  milestone payments in its oncology target discovery collaboration with
Ortho   Biotech   Oncology   Research  &  Development,  a  division  of  Janssen
Pharmaceutica.

In  the  fourth  quarter,  Galapagos  also  appointed  ABN AMRO Bank N.V. (to be
renamed The Royal Bank of Scotland N.V. in due course) as liquidity provider.

Forecasted revenue from Galapagos' seven alliances with pharmaceutical companies
and  visibility  into  the  BioFocus  order  book  encourage  management to give
guidance  for 2010 Group revenues above EUR120  million, with a positive cash flow
and a positive operating income for full year 2010.

These preliminary financial results have not been audited and could deviate from
actual results.

About Galapagos
Galapagos   <http://www.glpg.com/>  (Euronext:  GLPG;  OTC:  GLPYY)  is  a  drug
discovery and development company with small molecule programs in bone and joint
diseases,  metastatic cancer, cachexia, anti-infectives and metabolic diseases.
It   has  established  risk  sharing  alliances  with  GlaxoSmithKline,  Janssen
Pharmaceutica,  Lilly,  Merck  &  Co.  and  Roche.   Through  an  alliance  with
MorphoSys, Galapagos is also developing new antibody therapies in bone and joint
diseases.  Its division BioFocus offers a full suite of target-to-drug discovery
products  and services  to pharmaceutical  and biotech  companies and to patient
foundations,  encompassing target  discovery and  validation, screening and drug
discovery  through to delivery  of pre-clinical candidates.   Galapagos has more
than  500 employees  and  operates  facilities  in  six  countries,  with global
headquarters    in    Mechelen,    Belgium.     More   info   at:   www.glpg.com
<http://www.glpg.com/>


CONTACT

Onno van de Stolpe
CEO
Tel: + 31 62 909 8028
ir@glpg.com 


This   release   may  contain  forward-looking  statements,  including,  without
limitation,   statements   containing   the   words  "believes,"  "anticipates,"
"expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could,"
"stands   to,"   and   "continues,"   as   well  as  similar  expressions.  Such
forward-looking  statements may  involve known  and unknown risks, uncertainties
and  other factors  which might  cause the  actual results, financial condition,
performance  or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions, performance
or  achievements expressed or implied  by such forward-looking statements. Given
these  uncertainties, the reader is  advised not to place  any undue reliance on
such  forward-looking statements. These forward-looking statements speak only as
of  the date of publication of  this document. Galapagos expressly disclaims any
obligation  to update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.


[HUG#1378465]